newsfilter
← Latest News
PR Newswire·

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive

  • Faruqi & Faruqi, LLP is investigating potential federal securities class action claims against Unicycive Therapeutics, Inc. (NASDAQ: UNCY).
  • The lawsuit alleges the company overstated its readiness to satisfy FDA manufacturing compliance requirements & exaggerated regulatory prospects for the OLC NDA.
  • Investors who purchased Unicycive securities between March 29, 2024, & June 27, 2025, are encouraged to contact partner Josh Wilson to discuss legal rights.
  • The complaint cites two specific stock price drops: a 40.89% decline on June 10, 2025, following news of cGMP deficiencies at a third-party vendor, & a 29.85% drop on June 30, 2025, after the FDA issued a Complete Response Letter.
  • Investors must act by the October 14, 2025, deadline to seek the role of lead plaintiff in the federal case.
  • The firm is seeking information from whistleblowers, former employees, shareholders, & others regarding Unicycive's conduct.
  • Any communication with the firm regarding this matter will be treated in a confidential manner.